logo

GUFICBIO vs IPCALAB: Stock Comparison

GUFIC BIOSCIENCES vs IPCA LABORATORIESUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

IPCA LABORATORIES is the larger company by market capitalisation. GUFIC BIOSCIENCES shows faster revenue growth, while IPCA LABORATORIES shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

GUFICBIO leads 2; IPCALAB leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

GUFICBIOIPCALAB

Valuation lens

What price are you paying?

Market CapContext only
₹3,948 Cr
₹47,950 Cr
P/E RatioIPCALAB has the lower reading
53.78x
36.61x ✓
P/B RatioGUFICBIO has the lower reading
5.94x ✓
5.95x
EPSIPCALAB has the higher reading
₹2.22
₹15.84 ✓
Book ValueContext only
₹66.31
₹375.4
Dividend YieldIPCALAB has the higher reading
0.03%
0.31% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
IPCALAB is the larger company
₹47,950 Cr vs ₹3,948 Cr
P/E Ratio
IPCALAB has a lower P/E
36.61x vs 53.78x
P/B Ratio
GUFICBIO has a lower P/B
5.94x vs 5.95x
EPS
IPCALAB has higher earnings per share
₹15.84 vs ₹2.22
Dividend Yield
IPCALAB has a higher dividend yield
0.31% vs 0.03%
Revenue Growth (TTM YoY)
GUFICBIO has faster revenue growth
22.8% vs 6.2%
EPS Growth (TTM YoY)
IPCALAB has faster EPS growth
341.6% vs 183.1%
ROE
IPCALAB has a higher ROE
12.43% vs 9.66%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGUFICBIOIPCALAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGUFICBIOIPCALAB
Live Price₹394₹1,903.5
Day Change1.16%-0.8%
Volume1.11 L3.27 L
52-Week High₹467.8₹2,038
52-Week Low₹268₹1,251.6
Distance from 52W High-15.78%-6.6%

Valuation

MetricGUFICBIOIPCALAB
Market Cap₹3,948 Cr₹47,950 Cr
P/E Ratio53.78x36.61x
P/B Ratio5.94x5.95x
EPS₹2.22₹15.84
Book Value₹66.31₹375.4
Dividend Yield0.03%0.31%

Growth

MetricGUFICBIOIPCALAB
Revenue Growth (TTM YoY)22.8%6.2%
EPS Growth (TTM YoY)183.1%341.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricGUFICBIOIPCALAB
ROE9.66%12.43%
ROCE9.25%12.76%
Net Margin6.8%11.83%
Operating Margin13.05%17.09%
Debt to Equity0.58x0.07x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricGUFICBIOIPCALAB
Promoter Holding72.5%44.72%
FII Holding0.45%▼ 0.01 pp11.53%▲ 0.8 pp
DII Holding3.38%▼ 0.3 pp36.59%▼ 0.78 pp
Public Holding23.67%▲ 0.31 pp7.15%▼ 0.03 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GUFIC BIOSCIENCES and IPCA LABORATORIES.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.